{"ticker": {"uuid": "1c21f044-d0ca-4c28-ae24-6beaea5b60b7", "symbol": "HOWL", "name": "Werewolf Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Werewolf Therapeutics, Inc. \u2013 NASDAQ:HOWL", "summary": "This article provides a brief snapshot of the \"Price to earnings forward\" metric for Werewolf Therapeutics, Inc. (NASDAQ:HOWL) on TradingView. It shows the period, value, change, and percentage change. The content primarily focuses on the financial data point for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-HOWL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T04:39:08", "published_display": "12 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics, Inc. Net Debt / EBITDA (HOWL)", "summary": "This article provides an analysis of Werewolf Therapeutics, Inc.'s Net Debt / EBITDA ratio, a key leverage metric. The company's Net Debt / EBITDA decreased significantly from 1.07 in FY2024 to 0.41 in FY2025, with a trailing-twelve-month figure of 0.26 as of Q1 FY26. The report ", "url": "https://mlq.ai/companies/werewolf-therapeutics-inc/net-debt-to-ebitda/", "source_name": "MLQ.ai", "published_at": "2026-07-10T06:16:57", "published_display": "10 Jul 2026 06:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HOWL stock stays in focus as Werewolf Therapeutics pursues immuno-oncology pipeline", "summary": "Werewolf Therapeutics (HOWL) is a clinical-stage biotechnology company focused on developing novel immuno-oncology and immune-modulating therapies. The article discusses how HOWL stock reflects investor interest in the company's experimental pipeline, which targets cancer and aut", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/howl-stock-stays-in-focus-as-werewolf-therapeutics-pursues-immuno-oncology/69734200", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T19:54:00", "published_display": "09 Jul 2026 19:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares", "summary": "Werewolf Therapeutics director Luke Evnin's associated funds sold a total of 143,199 shares of Common Stock in open-market transactions on July 6 and July 7, 2026. These sales, executed under a pre-established Rule 10b5-1 trading plan, resulted in a weighted average price of $0.3", "url": "https://www.stocktitan.net/sec-filings/HOWL/form-4-werewolf-therapeutics-inc-insider-trading-activity-5261a8acc721.html", "source_name": "Stock Titan", "published_at": "2026-07-09T04:40:35", "published_display": "09 Jul 2026 04:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Werewolf Therapeutics Inc. on July 8, 2026, as reported by Investing.com. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of the company's stock. The article includes the stock sy", "url": "https://ng.investing.com/news/stock-market-news/form-4-werewolf-therapeutics-inc-for-8-july-93CH-2591971", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T04:11:47", "published_display": "09 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics director Luke Evnin sells $44,749 in stock", "summary": "Luke Evnin, a director at Werewolf Therapeutics, Inc. (NASDAQ:HOWL), sold 143,199 shares of common stock for a total of $44,749 over two days, July 6 and July 7, 2026. The sales were executed through a Rule 10b5-1 trading plan at prices ranging from $0.31 to $0.32 per share. Desp", "url": "https://www.investing.com/news/insider-trading-news/werewolf-therapeutics-director-luke-evnin-sells-44749-in-stock-93CH-4782686", "source_name": "Investing.com", "published_at": "2026-07-08T22:40:35", "published_display": "08 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech", "summary": "Werewolf Therapeutics (HOWL) is a clinical-stage biotech company listed on Nasdaq, focusing on immune-stimulating cancer therapies based on engineered cytokines. The company's strategy involves creating prodrugs that activate selectively in the tumor microenvironment to overcome ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/werewolf-therapeutics-outlines-its-immuno-oncology-strategy-as/69716051", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:11:06", "published_display": "07 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Werewolf Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Werewolf Therapeutics, Inc. (HOWL). The filing indicates a proposed sale of 21,194 shares of common stock with an aggregate market value of $7,214.44, acquired via a private placement in 2021. The article also provides details abou", "url": "https://www.stocktitan.net/sec-filings/HOWL/144-werewolf-therapeutics-inc-sec-filing-80873b3c7da0.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:40:43", "published_display": "06 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Inc (HOWL) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE94MXEzOFNTWk8wTVRiYUtkVmZvT3J1eTdjeUZ3RFMxQ2FuVkwzenFlS0J1N3lPUnZhSjZQTHh5aFJ4Y04xU1dHY1B3aWs3ZlduUW9oVWpySU5lRnRQbExQR0h0MERXMTJCN0J3TUVfUFM?oc=5", "source_name": "TradingKey", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold", "summary": "RA Capital Management and its affiliated funds have reduced their stake in Werewolf Therapeutics (HOWL) to 4.1%, falling below the 5% beneficial ownership threshold. This change was reported in an Amendment No. 12 to their Schedule 13D filing, detailing open market sales between ", "url": "https://www.stocktitan.net/sec-filings/HOWL/schedule-13d-a-werewolf-therapeutics-inc-amended-major-shareholder-re-177a21b46e45.html", "source_name": "Stock Titan", "published_at": "2026-07-03T01:13:18", "published_display": "03 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com", "summary": "Investing.com reports on a Form 13D/A filing for WEREWOLF THERAPEUTICS as of July 2nd. The article provides a brief mention of the filing along with updated market data and news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-13da-werewolf-therapeutics-for-2-july-93CH-4719453", "source_name": "Investing.com Canada", "published_at": "2026-07-03T00:13:18", "published_display": "03 Jul 2026 00:13", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38", "summary": "Werewolf Therapeutics (HOWL) has seen its price target increased by 20.19%, bringing it to $6.38. This adjustment indicates a more optimistic outlook for the company's stock from analysts.", "url": "http://www.msn.com/en-us/money/companies/werewolf-therapeutics-howl-price-target-increased-by-20-19-to-6-38/ar-AA1ZyW7v?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-02T06:10:34", "published_display": "02 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Werewolf Therapeutics, Inc.'s SEC filings and other financial documents, spanning from 2022 to 2026. It includes various earnings reports (10-K, 10-Q, 8-K), corporate event transcripts, and investor presentations, detailing the compan", "url": "https://www.tradingview.com/symbols/BOATS-HOWL/documents/", "source_name": "TradingView", "published_at": "2026-07-01T18:40:00", "published_display": "01 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Werewolf Therapeutics Inc (HOWL) related to June 29. It indicates insider transaction activity for the specified date. The piece also includes current stock market data for various indi", "url": "https://ng.investing.com/news/stock-market-news/form-4-werewolf-therapeutics-inc-for-29-june-93CH-2579117", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T00:14:00", "published_display": "30 Jun 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics director Luke Evnin sells $47,125 in stock", "summary": "Werewolf Therapeutics director Luke Evnin sold 157,084 shares of common stock for a total of $47,125 on June 29, 2026, at a weighted average price of $0.30 per share. The sale was executed through a Rule 10b5-1 trading plan and involved several entities. Following the transaction", "url": "https://www.investing.com/news/insider-trading-news/werewolf-therapeutics-director-luke-evnin-sells-47125-in-stock-93CH-4766695", "source_name": "Investing.com", "published_at": "2026-06-29T23:41:05", "published_display": "29 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares", "summary": "Entities associated with Werewolf Therapeutics director Luke Evnin sold 157,084 shares of HOWL common stock in an open-market transaction at a weighted average price of $0.30 per share. These sales were executed under a Rule 10b5-1 trading plan established on March 26, 2026. Afte", "url": "https://www.stocktitan.net/sec-filings/HOWL/form-4-werewolf-therapeutics-inc-insider-trading-activity-104eef7bd3dd.html", "source_name": "Stock Titan", "published_at": "2026-06-29T22:41:05", "published_display": "29 Jun 2026 22:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Inc (HOWL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Werewolf Therapeutics Inc (HOWL) has a current financial score of 6.80, placing it 206th out of 387 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The analysis highlights that relevant financial data for profitab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-howl/financial-health", "source_name": "TradingKey", "published_at": "2026-06-27T08:39:03", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales", "summary": "RA Capital Management and its associated funds have filed an amended Schedule 13D/A, disclosing a 6.0% beneficial ownership stake in Werewolf Therapeutics, Inc. (HOWL). This stake, totaling 2,915,742 shares, is held across RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fun", "url": "https://www.stocktitan.net/sec-filings/HOWL/schedule-13d-a-werewolf-therapeutics-inc-amended-major-shareholder-re-64caaebb88e8.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:09:48", "published_display": "26 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors", "summary": "Werewolf Therapeutics is advancing its conditionally activated cancer immunotherapies, specifically the WTX-124 and WTX-330 programs. The clinical-stage biotech aims to activate these INDUKINE molecules only in the tumor microenvironment to widen the therapeutic window for potent", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/werewolf-therapeutics-details-cancer-pipeline-progress-shares-watched-by/69635193", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T19:44:36", "published_display": "26 Jun 2026 19:44", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Behind the Recent Insider Selling at Werewolf Therapeutics (HOWL)", "summary": "Director Luke Evnin recently sold over $66,000 worth of Werewolf Therapeutics (HOWL) stock through a pre-arranged Rule 10b5-1 plan, suggesting routine portfolio management rather than a direct bearish signal. However, significant net insider selling, coupled with the company's fi", "url": "https://www.kavout.com/market-lens/what-s-behind-the-recent-insider-selling-at-werewolf-therapeutics-howl", "source_name": "Kavout | AI", "published_at": "2026-06-26T13:39:37", "published_display": "26 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL)", "summary": "This article provides an overview of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, such as upcoming earnings reports and past earnings per share, and addresses", "url": "https://www.tradingview.com/symbols/NASDAQ-HOWL/forecast-actuals-and-estimates/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-06-26T11:39:03", "published_display": "26 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics (Nasdaq:HOWL) - Stock Analysis", "summary": "Werewolf Therapeutics (Nasdaq:HOWL) is a biopharmaceutical company focused on developing therapeutics to stimulate the immune system for cancer and immune-mediated conditions. The stock has experienced significant volatility and decline, with a current market cap of US$15.7m and ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-howl/werewolf-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-25T12:10:27", "published_display": "25 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Werewolf Therapeutics Inc For: 22 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Werewolf Therapeutics Inc (HOWL) dated June 22. Form 4 reports changes in beneficial ownership of company stock by insiders. The article contains minimal descriptive content beyond the ", "url": "https://ca.investing.com/news/stock-market-news/form-4-werewolf-therapeutics-inc-for-22-june-93CH-4702190", "source_name": "Investing.com Canada", "published_at": "2026-06-23T22:09:56", "published_display": "23 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock", "summary": "RA Capital, a major shareholder in Werewolf Therapeutics (NASDAQ:HOWL), sold 416,911 shares of common stock totaling $145,918 on June 17, 2026, at prices between $0.34 and $0.39 per share. These transactions were carried out indirectly by RA Capital Healthcare Fund, L.P. and RA C", "url": "https://www.investing.com/news/insider-trading-news/ra-capital-sells-145918-of-werewolf-therapeutics-howl-stock-93CH-4754361", "source_name": "Investing.com", "published_at": "2026-06-22T23:41:23", "published_display": "22 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13D/A] Werewolf Therapeutics, Inc. Amended Major Shareholder Report", "summary": "RA Capital Management and related entities have filed Amendment No. 10 to their Schedule 13D/A for Werewolf Therapeutics, Inc. (HOWL), updating their beneficial ownership to 7.5%, or 3,654,307 shares. This filing reports multiple open market sales by RA Capital Healthcare Fund, L", "url": "https://www.stocktitan.net/sec-filings/HOWL/schedule-13d-a-werewolf-therapeutics-inc-amended-major-shareholder-re-267012d87468.html", "source_name": "Stock Titan", "published_at": "2026-06-22T23:41:22", "published_display": "22 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital funds trim Werewolf Therapeutics (HOWL) stake with 416,911-share sale", "summary": "Investment funds associated with RA Capital have sold 416,911 shares of Werewolf Therapeutics (HOWL) common stock in open-market transactions. The shares were sold at a weighted average price of $0.35, with individual trades ranging from $0.34 to $0.39. Following these sales, one", "url": "https://www.stocktitan.net/sec-filings/HOWL/form-4-werewolf-therapeutics-inc-insider-trading-activity-2b892af8d49c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:41:23", "published_display": "22 Jun 2026 22:41", "sentiment": "negative", "sentiment_pct": 28, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Inc. (HOWL) Q1 2026 Earnings: Narrower Loss Surprises, Stock Rises 3.6% - Earnings Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOcWV5ek45TF9zM3JlcVFTR3BXUVNlaVRuSHgxYTVIYzhMWnd4dVp0Tkk0U1JOMkE0UjFWTmhzbVZJZWZtTWx4eTNwdVZiLXpyV1pUZms2UDNTeWY3ODJCUEMtRnVqMXMyeFNBaHdsbkkzT0hVR2JfS09DdmdZYXR5OVV5LTVoU2tQSGZrdm85Zm1iX1F1aHlQM19TUGRwdk1YM09HcWhPMkEyeXRkZWVQWUFneDdlNkY2dXZKZTRtZVZoV1BKVjlrcXJwaU9MZw?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Werewolf Therapeutics Insider Sold Shares Worth $280,210, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/news/werewolf-therapeutics-insider-sold-shares-085413192.html", "source_name": "MT Newswires", "published_at": "2026-05-13T08:54:13+00:00", "published_display": "13 May 2026 08:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics director Luke Evnin sells $280,210 in company stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNTFhiVTViZk1iOTB3UmUyTmRVc0tIQTlUMDZiUGl2eHZjbTBKU2pjMmltNVF1eGVIS3cxVGN5VTg4RUd3elRHcGk0ZVpZU013d1RLYU9tUU5tU3BpR29TSXpmZ3R0VFVBN1FBS0N0cDhsWUJxMldfOW9rSUFUeTl4dzVsLXJ1dmt4WFJqMWFmclZWYnpPOWpaT3RQTEdSUGlXd19nUnpSV0VOTmFqSGVHT1FPOHVkdEZYLWh5eUdDZGF4U0pIWWctcWNBaHFDLUp4?oc=5", "source_name": "Investing.com India", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxNVE5CRlBHYmtYanlqLTFvVTk0ZEtnYWRLaG1PRFdhSDd3Zm91M2dPLUlYODN1LTA0VXFxRE5TaGYwcUg0aVlRS3lZSXZBQkdsVXZTQ2tkV01jQ3VDSHF4RlUtcDNfSTI0Q1g0NDBqMWVEWDh6NDN6T0RqYUhqQmJpTVMtSGk3eENTdVZncUNJUzF6Yk9SQ0JDTk5WZTBhZ1B3Z25kanBWaThRZDRHR1NWU3hISXoxajN1SWNLX3d6eVZMZUxNeGplR2paSWp5Sll5Z1F0VTk4RnczRWs2VTJKR0xfY1A0b0hFT3U1MTJaamoxc3g5ZE4teWttOA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQaW0wN21BUURQZ0ttQlJYaXg5bl9jRWpoSE16TXVBMDFIcVhlazFQdWk0X01EQ3NtQlRDb2VkWmVmUEpzU1cta0V5Q0piUzhxU090TllVOHlaMGQ2WEpvQ0hKOC1UaFZzcVhrcmluejIwZTNiZ00zRUdzNkhPSmxrbHZVdkdfQWpPU2UwYXB3dVZ5dGRfaVEybDBDdURkS05ZN0dOZm1KSUktdHAzazJxNEhFQkpHMlk4NUNiZTYwM1E1bHlfbGxjVnE4b0U?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics stock falls after announcing 64% workforce reduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPX1NCOWFYX2xER2ZGczNPYnlvdjFNRU9LNlI0UEpUUG9uOFFoOXFRUlhiMUYybG9yRDB0bGV1R0MwMy1BWUx3YzZLNVg5Q2tyaXhBM2h3UW1kSE81VGtxODc1S2pwcmtpaW52c01MUk8wMV90SnV6SlAtbnBRODNiTkpINElvNENFeU9ldUZtX0ZpUXAtRXhRQVhZQ2pOTUpkYjhDdVVTM0E3cE9PVnNBTGRGejB0SFNwa0gzOVViQktSUkxJRmtkSVhBNV85eDIt?oc=5", "source_name": "Investing.com", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics receives Nasdaq notice for minimum bid price deficiency", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNb0JTMkRjM3JnV1BEc0JtWUo0cEQ1aFotOVUwUy1jaUs5TUFiV3BtMG45eXE0eWxqWGhlZ0JJcDlkRHV5UW5UR3NONTdhRjdOam55UTNZUVJzeF9lWEVtS0ludVRvSUVjaTVBenlCdDA5cmRacFl5YWRsTEtUTTBUMmZsSFJTR21lbmJsSXl4STloUmRIMFdnQzNNcHl0WVpnUGdvRHp3R2o1RWx0alV4Nm5wMUVyRzhYY3VUXzVzTDBYcVpkZndJTlh5d25zUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting | HOWL Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQY2xvUF80OTVYZDl3Z05PWkx1Q19TYUNES0taME1KQ2dpRHdQb29rNUJBZDBHOUhnMUtXRFJWc1JaTWNTMmthRkxWenlma3hYdkFTUE9mUG5FU1lRRVZfQTJaSjh1N2F0cElzZGN2Tm5RcHB2S000S01EdGFmeXJrTlYzWFViZWlGcUtTeDZXcXpFZ0M5Z3BPOTl6UlY1R3VKdUI2WDZCMGpkdHhPV0ttdjBsbw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics (HOWL) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBOYWNiRktxdnZxRlRVSkVCOVhHTFlTaWtpTmtFb3lMMF9ORWVlcm95SnJJZE9FZXRWN0ZFdW5odzZVLWtYNVhSNE55WmtvbUlFREkyTEN2U1JLQQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-04-30T23:17:46+00:00", "published_display": "30 Apr 2021 23:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Werewolf Therapeutics, Inc. \u2013 NASDAQ:HOWL", "summary": "This article provides a brief snapshot of the \"Price to earnings forward\" metric for Werewolf Therapeutics, Inc. (NASDAQ:HOWL) on TradingView. It shows the period, value, change, and percentage change. The content primarily focuses on the financial data point for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-HOWL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T04:39:08", "published_display": "12 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics, Inc. Net Debt / EBITDA (HOWL)", "summary": "This article provides an analysis of Werewolf Therapeutics, Inc.'s Net Debt / EBITDA ratio, a key leverage metric. The company's Net Debt / EBITDA decreased significantly from 1.07 in FY2024 to 0.41 in FY2025, with a trailing-twelve-month figure of 0.26 as of Q1 FY26. The report ", "url": "https://mlq.ai/companies/werewolf-therapeutics-inc/net-debt-to-ebitda/", "source_name": "MLQ.ai", "published_at": "2026-07-10T06:16:57", "published_display": "10 Jul 2026 06:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HOWL stock stays in focus as Werewolf Therapeutics pursues immuno-oncology pipeline", "summary": "Werewolf Therapeutics (HOWL) is a clinical-stage biotechnology company focused on developing novel immuno-oncology and immune-modulating therapies. The article discusses how HOWL stock reflects investor interest in the company's experimental pipeline, which targets cancer and aut", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/howl-stock-stays-in-focus-as-werewolf-therapeutics-pursues-immuno-oncology/69734200", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T19:54:00", "published_display": "09 Jul 2026 19:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares", "summary": "Werewolf Therapeutics director Luke Evnin's associated funds sold a total of 143,199 shares of Common Stock in open-market transactions on July 6 and July 7, 2026. These sales, executed under a pre-established Rule 10b5-1 trading plan, resulted in a weighted average price of $0.3", "url": "https://www.stocktitan.net/sec-filings/HOWL/form-4-werewolf-therapeutics-inc-insider-trading-activity-5261a8acc721.html", "source_name": "Stock Titan", "published_at": "2026-07-09T04:40:35", "published_display": "09 Jul 2026 04:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Werewolf Therapeutics Inc. on July 8, 2026, as reported by Investing.com. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of the company's stock. The article includes the stock sy", "url": "https://ng.investing.com/news/stock-market-news/form-4-werewolf-therapeutics-inc-for-8-july-93CH-2591971", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T04:11:47", "published_display": "09 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics director Luke Evnin sells $44,749 in stock", "summary": "Luke Evnin, a director at Werewolf Therapeutics, Inc. (NASDAQ:HOWL), sold 143,199 shares of common stock for a total of $44,749 over two days, July 6 and July 7, 2026. The sales were executed through a Rule 10b5-1 trading plan at prices ranging from $0.31 to $0.32 per share. Desp", "url": "https://www.investing.com/news/insider-trading-news/werewolf-therapeutics-director-luke-evnin-sells-44749-in-stock-93CH-4782686", "source_name": "Investing.com", "published_at": "2026-07-08T22:40:35", "published_display": "08 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech", "summary": "Werewolf Therapeutics (HOWL) is a clinical-stage biotech company listed on Nasdaq, focusing on immune-stimulating cancer therapies based on engineered cytokines. The company's strategy involves creating prodrugs that activate selectively in the tumor microenvironment to overcome ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/werewolf-therapeutics-outlines-its-immuno-oncology-strategy-as/69716051", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:11:06", "published_display": "07 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Werewolf Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Werewolf Therapeutics, Inc. (HOWL). The filing indicates a proposed sale of 21,194 shares of common stock with an aggregate market value of $7,214.44, acquired via a private placement in 2021. The article also provides details abou", "url": "https://www.stocktitan.net/sec-filings/HOWL/144-werewolf-therapeutics-inc-sec-filing-80873b3c7da0.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:40:43", "published_display": "06 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Inc (HOWL) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE94MXEzOFNTWk8wTVRiYUtkVmZvT3J1eTdjeUZ3RFMxQ2FuVkwzenFlS0J1N3lPUnZhSjZQTHh5aFJ4Y04xU1dHY1B3aWs3ZlduUW9oVWpySU5lRnRQbExQR0h0MERXMTJCN0J3TUVfUFM?oc=5", "source_name": "TradingKey", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold", "summary": "RA Capital Management and its affiliated funds have reduced their stake in Werewolf Therapeutics (HOWL) to 4.1%, falling below the 5% beneficial ownership threshold. This change was reported in an Amendment No. 12 to their Schedule 13D filing, detailing open market sales between ", "url": "https://www.stocktitan.net/sec-filings/HOWL/schedule-13d-a-werewolf-therapeutics-inc-amended-major-shareholder-re-177a21b46e45.html", "source_name": "Stock Titan", "published_at": "2026-07-03T01:13:18", "published_display": "03 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com", "summary": "Investing.com reports on a Form 13D/A filing for WEREWOLF THERAPEUTICS as of July 2nd. The article provides a brief mention of the filing along with updated market data and news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-13da-werewolf-therapeutics-for-2-july-93CH-4719453", "source_name": "Investing.com Canada", "published_at": "2026-07-03T00:13:18", "published_display": "03 Jul 2026 00:13", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38", "summary": "Werewolf Therapeutics (HOWL) has seen its price target increased by 20.19%, bringing it to $6.38. This adjustment indicates a more optimistic outlook for the company's stock from analysts.", "url": "http://www.msn.com/en-us/money/companies/werewolf-therapeutics-howl-price-target-increased-by-20-19-to-6-38/ar-AA1ZyW7v?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-02T06:10:34", "published_display": "02 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Werewolf Therapeutics, Inc.'s SEC filings and other financial documents, spanning from 2022 to 2026. It includes various earnings reports (10-K, 10-Q, 8-K), corporate event transcripts, and investor presentations, detailing the compan", "url": "https://www.tradingview.com/symbols/BOATS-HOWL/documents/", "source_name": "TradingView", "published_at": "2026-07-01T18:40:00", "published_display": "01 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Werewolf Therapeutics Inc (HOWL) related to June 29. It indicates insider transaction activity for the specified date. The piece also includes current stock market data for various indi", "url": "https://ng.investing.com/news/stock-market-news/form-4-werewolf-therapeutics-inc-for-29-june-93CH-2579117", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T00:14:00", "published_display": "30 Jun 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics director Luke Evnin sells $47,125 in stock", "summary": "Werewolf Therapeutics director Luke Evnin sold 157,084 shares of common stock for a total of $47,125 on June 29, 2026, at a weighted average price of $0.30 per share. The sale was executed through a Rule 10b5-1 trading plan and involved several entities. Following the transaction", "url": "https://www.investing.com/news/insider-trading-news/werewolf-therapeutics-director-luke-evnin-sells-47125-in-stock-93CH-4766695", "source_name": "Investing.com", "published_at": "2026-06-29T23:41:05", "published_display": "29 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares", "summary": "Entities associated with Werewolf Therapeutics director Luke Evnin sold 157,084 shares of HOWL common stock in an open-market transaction at a weighted average price of $0.30 per share. These sales were executed under a Rule 10b5-1 trading plan established on March 26, 2026. Afte", "url": "https://www.stocktitan.net/sec-filings/HOWL/form-4-werewolf-therapeutics-inc-insider-trading-activity-104eef7bd3dd.html", "source_name": "Stock Titan", "published_at": "2026-06-29T22:41:05", "published_display": "29 Jun 2026 22:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Inc (HOWL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Werewolf Therapeutics Inc (HOWL) has a current financial score of 6.80, placing it 206th out of 387 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The analysis highlights that relevant financial data for profitab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-howl/financial-health", "source_name": "TradingKey", "published_at": "2026-06-27T08:39:03", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales", "summary": "RA Capital Management and its associated funds have filed an amended Schedule 13D/A, disclosing a 6.0% beneficial ownership stake in Werewolf Therapeutics, Inc. (HOWL). This stake, totaling 2,915,742 shares, is held across RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fun", "url": "https://www.stocktitan.net/sec-filings/HOWL/schedule-13d-a-werewolf-therapeutics-inc-amended-major-shareholder-re-64caaebb88e8.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:09:48", "published_display": "26 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors", "summary": "Werewolf Therapeutics is advancing its conditionally activated cancer immunotherapies, specifically the WTX-124 and WTX-330 programs. The clinical-stage biotech aims to activate these INDUKINE molecules only in the tumor microenvironment to widen the therapeutic window for potent", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/werewolf-therapeutics-details-cancer-pipeline-progress-shares-watched-by/69635193", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T19:44:36", "published_display": "26 Jun 2026 19:44", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Behind the Recent Insider Selling at Werewolf Therapeutics (HOWL)", "summary": "Director Luke Evnin recently sold over $66,000 worth of Werewolf Therapeutics (HOWL) stock through a pre-arranged Rule 10b5-1 plan, suggesting routine portfolio management rather than a direct bearish signal. However, significant net insider selling, coupled with the company's fi", "url": "https://www.kavout.com/market-lens/what-s-behind-the-recent-insider-selling-at-werewolf-therapeutics-howl", "source_name": "Kavout | AI", "published_at": "2026-06-26T13:39:37", "published_display": "26 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL)", "summary": "This article provides an overview of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, such as upcoming earnings reports and past earnings per share, and addresses", "url": "https://www.tradingview.com/symbols/NASDAQ-HOWL/forecast-actuals-and-estimates/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-06-26T11:39:03", "published_display": "26 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics (Nasdaq:HOWL) - Stock Analysis", "summary": "Werewolf Therapeutics (Nasdaq:HOWL) is a biopharmaceutical company focused on developing therapeutics to stimulate the immune system for cancer and immune-mediated conditions. The stock has experienced significant volatility and decline, with a current market cap of US$15.7m and ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-howl/werewolf-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-25T12:10:27", "published_display": "25 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Werewolf Therapeutics Inc For: 22 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Werewolf Therapeutics Inc (HOWL) dated June 22. Form 4 reports changes in beneficial ownership of company stock by insiders. The article contains minimal descriptive content beyond the ", "url": "https://ca.investing.com/news/stock-market-news/form-4-werewolf-therapeutics-inc-for-22-june-93CH-4702190", "source_name": "Investing.com Canada", "published_at": "2026-06-23T22:09:56", "published_display": "23 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock", "summary": "RA Capital, a major shareholder in Werewolf Therapeutics (NASDAQ:HOWL), sold 416,911 shares of common stock totaling $145,918 on June 17, 2026, at prices between $0.34 and $0.39 per share. These transactions were carried out indirectly by RA Capital Healthcare Fund, L.P. and RA C", "url": "https://www.investing.com/news/insider-trading-news/ra-capital-sells-145918-of-werewolf-therapeutics-howl-stock-93CH-4754361", "source_name": "Investing.com", "published_at": "2026-06-22T23:41:23", "published_display": "22 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13D/A] Werewolf Therapeutics, Inc. Amended Major Shareholder Report", "summary": "RA Capital Management and related entities have filed Amendment No. 10 to their Schedule 13D/A for Werewolf Therapeutics, Inc. (HOWL), updating their beneficial ownership to 7.5%, or 3,654,307 shares. This filing reports multiple open market sales by RA Capital Healthcare Fund, L", "url": "https://www.stocktitan.net/sec-filings/HOWL/schedule-13d-a-werewolf-therapeutics-inc-amended-major-shareholder-re-267012d87468.html", "source_name": "Stock Titan", "published_at": "2026-06-22T23:41:22", "published_display": "22 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital funds trim Werewolf Therapeutics (HOWL) stake with 416,911-share sale", "summary": "Investment funds associated with RA Capital have sold 416,911 shares of Werewolf Therapeutics (HOWL) common stock in open-market transactions. The shares were sold at a weighted average price of $0.35, with individual trades ranging from $0.34 to $0.39. Following these sales, one", "url": "https://www.stocktitan.net/sec-filings/HOWL/form-4-werewolf-therapeutics-inc-insider-trading-activity-2b892af8d49c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:41:23", "published_display": "22 Jun 2026 22:41", "sentiment": "negative", "sentiment_pct": 28, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Inc. (HOWL) Q1 2026 Earnings: Narrower Loss Surprises, Stock Rises 3.6% - Earnings Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOcWV5ek45TF9zM3JlcVFTR3BXUVNlaVRuSHgxYTVIYzhMWnd4dVp0Tkk0U1JOMkE0UjFWTmhzbVZJZWZtTWx4eTNwdVZiLXpyV1pUZms2UDNTeWY3ODJCUEMtRnVqMXMyeFNBaHdsbkkzT0hVR2JfS09DdmdZYXR5OVV5LTVoU2tQSGZrdm85Zm1iX1F1aHlQM19TUGRwdk1YM09HcWhPMkEyeXRkZWVQWUFneDdlNkY2dXZKZTRtZVZoV1BKVjlrcXJwaU9MZw?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Insider Sold Shares Worth $280,210, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/news/werewolf-therapeutics-insider-sold-shares-085413192.html", "source_name": "MT Newswires", "published_at": "2026-05-13T08:54:13+00:00", "published_display": "13 May 2026 08:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics director Luke Evnin sells $280,210 in company stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNTFhiVTViZk1iOTB3UmUyTmRVc0tIQTlUMDZiUGl2eHZjbTBKU2pjMmltNVF1eGVIS3cxVGN5VTg4RUd3elRHcGk0ZVpZU013d1RLYU9tUU5tU3BpR29TSXpmZ3R0VFVBN1FBS0N0cDhsWUJxMldfOW9rSUFUeTl4dzVsLXJ1dmt4WFJqMWFmclZWYnpPOWpaT3RQTEdSUGlXd19nUnpSV0VOTmFqSGVHT1FPOHVkdEZYLWh5eUdDZGF4U0pIWWctcWNBaHFDLUp4?oc=5", "source_name": "Investing.com India", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxNVE5CRlBHYmtYanlqLTFvVTk0ZEtnYWRLaG1PRFdhSDd3Zm91M2dPLUlYODN1LTA0VXFxRE5TaGYwcUg0aVlRS3lZSXZBQkdsVXZTQ2tkV01jQ3VDSHF4RlUtcDNfSTI0Q1g0NDBqMWVEWDh6NDN6T0RqYUhqQmJpTVMtSGk3eENTdVZncUNJUzF6Yk9SQ0JDTk5WZTBhZ1B3Z25kanBWaThRZDRHR1NWU3hISXoxajN1SWNLX3d6eVZMZUxNeGplR2paSWp5Sll5Z1F0VTk4RnczRWs2VTJKR0xfY1A0b0hFT3U1MTJaamoxc3g5ZE4teWttOA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQaW0wN21BUURQZ0ttQlJYaXg5bl9jRWpoSE16TXVBMDFIcVhlazFQdWk0X01EQ3NtQlRDb2VkWmVmUEpzU1cta0V5Q0piUzhxU090TllVOHlaMGQ2WEpvQ0hKOC1UaFZzcVhrcmluejIwZTNiZ00zRUdzNkhPSmxrbHZVdkdfQWpPU2UwYXB3dVZ5dGRfaVEybDBDdURkS05ZN0dOZm1KSUktdHAzazJxNEhFQkpHMlk4NUNiZTYwM1E1bHlfbGxjVnE4b0U?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics stock falls after announcing 64% workforce reduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPX1NCOWFYX2xER2ZGczNPYnlvdjFNRU9LNlI0UEpUUG9uOFFoOXFRUlhiMUYybG9yRDB0bGV1R0MwMy1BWUx3YzZLNVg5Q2tyaXhBM2h3UW1kSE81VGtxODc1S2pwcmtpaW52c01MUk8wMV90SnV6SlAtbnBRODNiTkpINElvNENFeU9ldUZtX0ZpUXAtRXhRQVhZQ2pOTUpkYjhDdVVTM0E3cE9PVnNBTGRGejB0SFNwa0gzOVViQktSUkxJRmtkSVhBNV85eDIt?oc=5", "source_name": "Investing.com", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics receives Nasdaq notice for minimum bid price deficiency", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNb0JTMkRjM3JnV1BEc0JtWUo0cEQ1aFotOVUwUy1jaUs5TUFiV3BtMG45eXE0eWxqWGhlZ0JJcDlkRHV5UW5UR3NONTdhRjdOam55UTNZUVJzeF9lWEVtS0ludVRvSUVjaTVBenlCdDA5cmRacFl5YWRsTEtUTTBUMmZsSFJTR21lbmJsSXl4STloUmRIMFdnQzNNcHl0WVpnUGdvRHp3R2o1RWx0alV4Nm5wMUVyRzhYY3VUXzVzTDBYcVpkZndJTlh5d25zUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting | HOWL Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQY2xvUF80OTVYZDl3Z05PWkx1Q19TYUNES0taME1KQ2dpRHdQb29rNUJBZDBHOUhnMUtXRFJWc1JaTWNTMmthRkxWenlma3hYdkFTUE9mUG5FU1lRRVZfQTJaSjh1N2F0cElzZGN2Tm5RcHB2S000S01EdGFmeXJrTlYzWFViZWlGcUtTeDZXcXpFZ0M5Z3BPOTl6UlY1R3VKdUI2WDZCMGpkdHhPV0ttdjBsbw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Werewolf Therapeutics (HOWL) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBOYWNiRktxdnZxRlRVSkVCOVhHTFlTaWtpTmtFb3lMMF9ORWVlcm95SnJJZE9FZXRWN0ZFdW5odzZVLWtYNVhSNE55WmtvbUlFREkyTEN2U1JLQQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-04-30T23:17:46+00:00", "published_display": "30 Apr 2021 23:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 76, "total_relevant": 44, "sentiment_summary": {"positive": 6, "negative": 15, "neutral": 23, "score": 47, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 15}, "market_context": {"has_market_context": true, "latest_close": 0.4, "latest_week": "2026-07-10", "one_week_move": 18.4, "four_week_move": 5.8, "twelve_week_move": -57.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.509906, "market_dynamics_buy_signal": false, "relative_strength": -63.787354, "fair_value_gap": -81.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.6375, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+18.4% over one week, +5.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 5}, {"label": "Investing.com", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Ad-hoc-news.de", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 13}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+18.4% over one week, +5.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Werewolf Therapeutics, Inc. \u2013 NASDAQ:HOWL"}], "updated_at": "2026-07-16T08:07:35.936399+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}